Cardiac Health

Overview

Cardiac peptide therapy targets cardiomyocyte protection, mitochondrial function in heart muscle, post-ischemic repair, and GH-axis-related cardiometabolic benefits. The heart is highly energy-demanding and particularly vulnerable to mitochondrial dysfunction and oxidative stress. Peptides in this category are not replacements for established cardiac medications but may serve as adjuncts for metabolic and regenerative support.

Recommended Peptides

SS-31 – binds cardiolipin in the inner mitochondrial membrane; reduces ROS generation, preserves mitochondrial cristae integrity, and improves cardiac function post-ischemia; one of the most promising cardiac peptides in development
TB-500 – promotes cardiomyocyte survival after ischemic injury; upregulates Akt signaling; also supports vascular repair and angiogenesis in cardiac tissue
Hexarelin – GHRP with direct cardioprotective effects independent of GH release; binds CD36 receptors on cardiomyocytes; reduces cardiac fibrosis and improves post-MI function
Tesamorelin – GHRH analogue that reduces visceral fat (a major cardiac risk driver), improves lipid profiles, and may improve cardiac function via GH axis effects

Protocols

Related Conditions

Research Summary

TB-500 (Thymosin Beta-4) prevents cardiac rupture and improves cardiac function post-MI in mice by reducing inflammation and enhancing angiogenesis (PMID-25015963). Cardioprotection mechanisms include epicardial progenitor cell activation and antifibrotic effects (PMID-27450736). Semaglutide's SELECT trial demonstrated 20% MACE reduction in patients with obesity (PMID-37952131). GnRH antagonists show lower MACE rates than agonists in prostate cancer patients (PMID-37969642).

#condition #cardiovascular